{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-24-000011","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.122429+00:00","generated_at":"2026-06-07T00:57:30.066719+00:00","sec_items":["2.02","3.02","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Praxis licenses ulixacaltamide to Tenacia for Greater China; PRAX-628 Phase 2a PPR data positive; $81.3M cash","bullets":["Entered exclusive collaboration with Tenacia Biotechnology for ulixacaltamide in essential tremor in Greater China.","Issued 443,253 shares to BCPE (Bain Capital affiliate) at $22.5605/share (~20% premium) for $10M aggregate.","Preliminary cash and equivalents as of Dec 31, 2023: $81.3 million.","PRAX-628 Phase 2a PPR study: preliminary analysis of 15 mg cohort exceeded expectations; full data Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-24-000011","json":"https://secwatch.observer/filing/0001689548-24-000011.json","markdown":"https://secwatch.observer/filing/0001689548-24-000011.md","text":"https://secwatch.observer/filing/0001689548-24-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000011/0001689548-24-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000011/prax-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:57:30.066719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}